JP2008516945A - 置換されたアミノ化合物およびそれらの使用 - Google Patents

置換されたアミノ化合物およびそれらの使用 Download PDF

Info

Publication number
JP2008516945A
JP2008516945A JP2007536655A JP2007536655A JP2008516945A JP 2008516945 A JP2008516945 A JP 2008516945A JP 2007536655 A JP2007536655 A JP 2007536655A JP 2007536655 A JP2007536655 A JP 2007536655A JP 2008516945 A JP2008516945 A JP 2008516945A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heterocyclyl
nhc
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007536655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516945A5 (enExample
Inventor
ジェフリー・スコット・アルバート
ドン・アンディシク
ジェイムズ・アーノルド
ディーン・ブラウン
オーウェン・カラハン
ジェイムズ・キャンベル
ロビン・アーサー・エリス・カー
ジャンニ・チェッサーリ
マイルズ・ステュアート・コングリーヴ
フィル・エドワーズ
ジェイムズ・アール・エムプフィールド
マーティン・フレデリクソン
ジェラード・エム・ケーター
ジェニファー・クラムライン
ラス・モーガー
クリストファー・ウィリアム・マレー
サーヒル・パテール
マーク・シルヴェスター
スコット・スローナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
AstraZeneca AB
Original Assignee
Astex Therapeutics Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd, AstraZeneca AB filed Critical Astex Therapeutics Ltd
Publication of JP2008516945A publication Critical patent/JP2008516945A/ja
Publication of JP2008516945A5 publication Critical patent/JP2008516945A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007536655A 2004-10-15 2005-10-14 置換されたアミノ化合物およびそれらの使用 Pending JP2008516945A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61930904P 2004-10-15 2004-10-15
PCT/SE2005/001533 WO2006041404A1 (en) 2004-10-15 2005-10-14 Substituted amino-compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2008516945A true JP2008516945A (ja) 2008-05-22
JP2008516945A5 JP2008516945A5 (enExample) 2008-11-20

Family

ID=36148580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536655A Pending JP2008516945A (ja) 2004-10-15 2005-10-14 置換されたアミノ化合物およびそれらの使用

Country Status (5)

Country Link
US (1) US20090221579A1 (enExample)
EP (1) EP1802587A4 (enExample)
JP (1) JP2008516945A (enExample)
CN (1) CN101084199A (enExample)
WO (1) WO2006041404A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533602A (ja) * 2009-07-22 2012-12-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合アミノジヒドロピリミドン誘導体
JP2013533295A (ja) * 2010-08-09 2013-08-22 エフ．ホフマン−ラ ロシュ アーゲー １，４，５，６−テトラヒドロ−ピリミジン−２−イルアミン化合物
JP2014507427A (ja) * 2011-02-02 2014-03-27 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２インヒビターとしての１，４−オキサジン類
JP2014514302A (ja) * 2011-04-13 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害薬としての５−置換されたイミノチアジン類およびそれのモノおよびジオキシド、組成物およびそれらの使用
JP2018513191A (ja) * 2015-04-21 2018-05-24 オールジェネシス バイオセラピューティクス インコーポレイテッド Ｂａｃｅ１阻害剤としての化合物およびそれらの使用
JP2019501138A (ja) * 2015-11-25 2019-01-17 ユーシービー バイオファルマ エスピーアールエル プラスメプシンｖ阻害薬としてのイミノテトラヒドロピリミジノン誘導体

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
CN101360722A (zh) * 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶衍生物及其用途
CN101360721A (zh) * 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物或2-氨基吡啶酮衍生物及其用途
AR058381A1 (es) * 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
CN101460480A (zh) * 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
EP2644600B1 (en) * 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
CN100439343C (zh) * 2006-08-04 2008-12-03 复旦大学 2-烷基硫-5-烷基-6-(1-氰基芳甲基)取代尿嘧啶类化合物及其制备方法和用途
JP2010512390A (ja) * 2006-12-12 2010-04-22 シェーリング コーポレイション 三環式系を含むアスパルチルプロテアーゼ阻害剤
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
JP5450407B2 (ja) * 2007-07-06 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
KR20110048491A (ko) 2008-07-28 2011-05-11 에자이 알앤드디 매니지먼트 가부시키가이샤 스피로아미노디하이드로티아진 유도체들
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
ES2539859T3 (es) 2008-09-30 2015-07-06 Eisai R&D Management Co., Ltd. Nuevo derivado de aminodihidrotiazina condensado
EP2360155A4 (en) * 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US20120015961A1 (en) 2009-03-31 2012-01-19 Shionogi & Co., Ltd. Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US7964594B1 (en) * 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
ES2450568T3 (es) 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
MX2012010658A (es) 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
WO2012069428A1 (en) 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US8957083B2 (en) 2010-11-23 2015-02-17 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
SG191710A1 (en) 2011-01-21 2013-08-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
WO2013028670A1 (en) 2011-08-22 2013-02-28 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
WO2013041621A1 (de) 2011-09-20 2013-03-28 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
AU2013265376B2 (en) * 2012-05-24 2017-07-20 F. Hoffmann-La Roche Ag 5-amino[1,4]thiazines as BACE 1 inhibitors
WO2014010748A1 (en) * 2012-07-10 2014-01-16 Shionogi & Co., Ltd. Cyclopropane derivative having bace1 inhibiting activity
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
US20220289685A1 (en) 2019-08-19 2022-09-15 UCB Biopharma SRL Antimalarial hexahydropyrimidine analogues
GB202010606D0 (en) 2020-07-10 2020-08-26 Ucb Biopharma Sprl Therapeutic agents
US20250134890A1 (en) 2022-02-08 2025-05-01 UCB Biopharma SRL Antimalarial hexahydropyrimidine analogues

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019801A1 (en) * 1999-09-16 2001-03-22 Rimma Iliinichna Ashkinazi Bioactive substance containing derivatives of 2-amino-6-aryloxypyrimidines and intermediary products of synthesis thereof
WO2001070683A2 (en) * 2000-03-23 2001-09-27 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
JP2002525366A (ja) * 1998-09-25 2002-08-13 三菱化学株式会社 ピリミドン誘導体
WO2002096867A2 (en) * 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
WO2003015776A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
JP2003523380A (ja) * 2000-02-25 2003-08-05 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
WO2004016605A1 (en) * 2002-08-19 2004-02-26 Fujisawa Pharmaceutical Co., Ltd. 2-aminopyrimidine derivatives as adenosine a1 and a2a receptor antagonists
WO2004055007A1 (en) * 2002-12-16 2004-07-01 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2004085408A1 (en) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 2, 3, 6-trisubstituted-4-pyrimidone derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625026A (en) * 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
US6777420B2 (en) * 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
US20030114445A1 (en) * 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
KR20080025079A (ko) * 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
CN101193892A (zh) * 2005-06-14 2008-06-04 先灵公司 大环杂环天冬氨酰基蛋白酶抑制剂
US7763606B2 (en) * 2005-10-27 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7560451B2 (en) * 2005-10-31 2009-07-14 Schering Corporation Aspartyl protease inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525366A (ja) * 1998-09-25 2002-08-13 三菱化学株式会社 ピリミドン誘導体
WO2001019801A1 (en) * 1999-09-16 2001-03-22 Rimma Iliinichna Ashkinazi Bioactive substance containing derivatives of 2-amino-6-aryloxypyrimidines and intermediary products of synthesis thereof
JP2003523380A (ja) * 2000-02-25 2003-08-05 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
WO2001070683A2 (en) * 2000-03-23 2001-09-27 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2002096867A2 (en) * 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
WO2003015776A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2004016605A1 (en) * 2002-08-19 2004-02-26 Fujisawa Pharmaceutical Co., Ltd. 2-aminopyrimidine derivatives as adenosine a1 and a2a receptor antagonists
WO2004055007A1 (en) * 2002-12-16 2004-07-01 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
WO2004085408A1 (en) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 2, 3, 6-trisubstituted-4-pyrimidone derivatives

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533602A (ja) * 2009-07-22 2012-12-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合アミノジヒドロピリミドン誘導体
JP2013533295A (ja) * 2010-08-09 2013-08-22 エフ．ホフマン−ラ ロシュ アーゲー １，４，５，６−テトラヒドロ−ピリミジン−２−イルアミン化合物
JP2014507427A (ja) * 2011-02-02 2014-03-27 エフ．ホフマン−ラ ロシュ アーゲー Ｂａｃｅ１及び／又はｂａｃｅ２インヒビターとしての１，４−オキサジン類
JP2014514302A (ja) * 2011-04-13 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害薬としての５−置換されたイミノチアジン類およびそれのモノおよびジオキシド、組成物およびそれらの使用
JP2018513191A (ja) * 2015-04-21 2018-05-24 オールジェネシス バイオセラピューティクス インコーポレイテッド Ｂａｃｅ１阻害剤としての化合物およびそれらの使用
JP2019501138A (ja) * 2015-11-25 2019-01-17 ユーシービー バイオファルマ エスピーアールエル プラスメプシンｖ阻害薬としてのイミノテトラヒドロピリミジノン誘導体

Also Published As

Publication number Publication date
EP1802587A1 (en) 2007-07-04
EP1802587A4 (en) 2010-02-17
US20090221579A1 (en) 2009-09-03
CN101084199A (zh) 2007-12-05
WO2006041404A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
JP2008516945A (ja) 置換されたアミノ化合物およびそれらの使用
JP2008516946A (ja) 置換されたアミノ−ピリミドンおよびそれらの使用
US20080293709A1 (en) Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies
US20090215801A9 (en) Novel 2-Aminopyrimidinone Derivatives And Their Use
US7855213B2 (en) Compounds
JP2008523139A (ja) 置換アミノピリジン類及びその使用
WO2007058601A1 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
US20080318985A1 (en) Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use
JP2009515950A (ja) 新規な２−アミノピリミジン誘導体およびその使用
HK1127036A (en) Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
JPH11335373A (ja) アリールメチレンピペリジノピリミジン誘導体
HK1127034A (en) Novel 2-aminopyrimidine derivatives and their use
HK1127035A (en) Novel 2-aminopyrimidinone derivatives and their use
MX2008005985A (es) Compuestos iv y usos de los mismos
HK1127038A (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120522